As global health threats continue to evolve rapidly, pharmaceutical leaders face mounting pressure to design development programs that can withstand volatility. From pandemics to geopolitical unrest ...

Approximately 70 million people that live, work or vacation in areas of the U.S. in which Lyme disease is endemic could potentially benefit from pre-exposure prophylaxis TNX-4800 was studied in a ...

Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and ...

The Department of Health and Human Services, Office of Inspector General (“OIG”) recently released a favorable advisory opinion, OIG Advisory Opinion No. 24-11 (the “Opinion”), to a pharmaceutical ...

MALVERN, Pa., March 18, 2025 /PRNewswire/ -- MAXONA Pharmaceuticals today announced the preliminary results of the Phase 1 clinical program for MAX-001, which is in development as a New Molecular ...

Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions and integrated payment processing for the life sciences industries, today announced its ...

The latest update is out from Daito Pharmaceutical Co., Ltd. ( ($JP:4577) ). Daito Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company ...